Insmed, Inc. $INSM Stock Holdings Lowered by Renaissance Technologies LLC

Renaissance Technologies LLC cut its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 21.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,300 shares of the biopharmaceutical company’s stock after selling 5,600 shares during the period. Renaissance Technologies LLC’s holdings in Insmed were worth $3,319,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Gabelli Funds LLC increased its holdings in shares of Insmed by 46.7% in the first quarter. Gabelli Funds LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $442,000 after buying an additional 860 shares in the last quarter. Compound Planning Inc. boosted its stake in shares of Insmed by 0.8% during the 1st quarter. Compound Planning Inc. now owns 27,862 shares of the biopharmaceutical company’s stock worth $4,556,000 after acquiring an additional 211 shares in the last quarter. Inceptionr LLC bought a new stake in shares of Insmed during the 1st quarter worth $846,000. Sei Investments Co. grew its holdings in shares of Insmed by 56.8% in the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock worth $228,239,000 after acquiring an additional 505,624 shares during the last quarter. Finally, Lido Advisors LLC grew its holdings in shares of Insmed by 27.5% in the 1st quarter. Lido Advisors LLC now owns 1,980 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 427 shares during the last quarter.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: BRINSUPRI sales significantly exceeded expectations. Second-quarter revenue reached $309.2 million, up 49% from the first quarter, reflecting strong commercial uptake of the company’s bronchiectasis treatment. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.40 billion and increased its peak-sales estimate to more than $7 billion. Insmed Second-Quarter 2026 Results
• Positive Sentiment: Insmed beat quarterly estimates. Total revenue was $425.5 million, up 296.1% year over year and above the approximately $393.7 million consensus forecast. The company reported a loss of $0.06 per share, substantially narrower than the expected $0.67 loss and the $1.70 loss recorded a year earlier. Insmed Tops Q2 Earnings Estimates
• Positive Sentiment: Long-term growth expectations improved. Insmed lifted its combined peak-revenue outlook for BRINSUPRI, TPIP and ARIKAYCE to more than $14 billion, including over $6 billion for TPIP. It maintained 2026 ARIKAYCE revenue guidance of $450 million-$470 million and provided total 2026 revenue guidance of approximately $1.7 billion-$1.9 billion.
• Positive Sentiment: Trading activity signaled strong investor interest. Call-option volume rose roughly 469% above average, while reports described the stock as gaining about 30%-34% following the earnings release. Analysts also maintained an overall “Buy” recommendation.
• Neutral Sentiment: Profitability remains limited. Despite the improved loss, Insmed continues to report negative net income and return on equity as it invests in developing and commercializing its pipeline.

Analysts Set New Price Targets

Several equities research analysts have recently commented on INSM shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $175.00 target price on shares of Insmed in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research note on Friday, July 17th. Mizuho set a $192.00 price objective on Insmed in a report on Tuesday, June 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $235.00 price objective on shares of Insmed in a research note on Tuesday, July 28th. Finally, Evercore reaffirmed an “outperform” rating and set a $170.00 price objective on shares of Insmed in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $205.26.

Insiders Place Their Bets

In other Insmed news, insider Michael Alexander Smith sold 6,149 shares of Insmed stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $108.47, for a total transaction of $666,982.03. Following the transaction, the insider owned 41,613 shares of the company’s stock, valued at $4,513,762.11. The trade was a 12.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO William Lewis sold 21,398 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the completion of the sale, the chief executive officer directly owned 258,917 shares of the company’s stock, valued at $26,751,304.44. This trade represents a 7.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 54,590 shares of company stock worth $5,793,738. Insiders own 2.10% of the company’s stock.

Insmed Stock Performance

Shares of Insmed stock opened at $131.10 on Friday. The stock has a market cap of $28.42 billion, a PE ratio of -31.90 and a beta of 0.81. The business has a fifty day simple moving average of $105.14 and a 200-day simple moving average of $129.23. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 12 month low of $90.39 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.61. The firm had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. Insmed had a negative return on equity of 122.43% and a negative net margin of 76.94%.Insmed’s quarterly revenue was up 296.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.70) earnings per share. On average, sell-side analysts anticipate that Insmed, Inc. will post -2.37 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.